PD-L1 expression and pattern of immune cells in pre-treatment specimens are associated with disease-free survival for HR-NMIBC undergoing BCG treatment.
Mathieu RoumiguiéEva CompératLéonor ChaltielFrançois Xavier NouhaudGregory VerhoestAlexandra Masson-LecomtePierre ColinFrançois AudenetNadine HouédéStéphane LarréEvanguelos XylinasSerge BrunelleJeanne Piana-ThomassinJuliette CotteGéraldine PignotYann NeuzilletMorgan RouprêtPublished in: World journal of urology (2020)
Despite an association between PD-L1 expression and BCG failure in HR-NMIBC, the PD-L1 + status was not a prognostic factor in the response of BCG. Moreover, we confirmed the key role played by the IC within the microenvironment in BCG treatment. These findings highlighted the rationale to combine BCG and PD-L1/PD-1 antibodies in early bladder cancer.